in order to contribute to the development of adoptive immunotherapy against malignant brain tumors , the pharmacokinetics and toxicity of intrathecally administered recombinant interleukin-2 in dogs and human patients were analyzed .
C0021756
recombinant interleukin-2
C0086418
human